Antiretroviral News and Research

RSS

Greek health system suffers amid growing economic crisis

Reuters examines how a worsening economic crisis in Greece is affecting the country's health system, highlighting a 36 percent decrease in health spending by Greeks this year, according to the National School of Public Health, and an increase of more than 50 percent in new cases of HIV from the first five months of 2010 to the same period this year.

11 Nov 2011

Children's Hospital project to investigate effectiveness of BET antagonists against HIV

Terri Finkel, M.D., Ph.D., chief of Rheumatology at Children's Hospital and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, will pursue an innovative global health research project, titled "Use of a BET Antagonist to Control and Cure HIV Infection."

8 Nov 2011

CRCHUM researcher receives Gates Foundation grant to eradicate HIV/AIDS

The Centre de recherche du Centre hospitalier de l'Universit- de Montr-al (CRCHUM) announced today that one of its researchers will receive funding of 100,000 US $ through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges.

7 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011

Kenyan company receives WHO prequalification for generic ARV

"The cost of HIV/AIDS medicine is expected to drop by 30 percent in Kenya, enabling more people to access life-prolonging drugs, after the World Health Organization (WHO) gave the green light to a local company manufacturing generics, The Star newspaper reported on Wednesday," AlertNet reports.

4 Nov 2011

NYUCN to study 'Test and Linkage to Care Among Injecting Drug Users Kenya'

New York University College of Nursing (NYUCN) received a five-year, $4,161,665.00 grant from the National Institute of Health's National Institute on Drug Abuse (NIH/NIDA) to research "Test and Linkage to Care Among Injecting Drug Users (TLC_IDU) Kenya."

29 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

Foreign aid investment saves millions of lives, reflects American leadership

Chris Collins, vice president and director of public policy at the Foundation for AIDS Research (amfAR), and Khai Hoan Tram, an Allan Rosenfield Fellow at amfAR, write in this Huffington Post opinion piece that what's missing from the discussion of foreign aid -- which accounts for approximately one percent of the U.S. national budget -- "is the fact that [it] is actually used to aid those in need while advancing our country's humanitarian and diplomatic goals.

28 Oct 2011

Gilead submits Quad NDA to FDA for treatment of HIV-1 infection

Gilead Sciences, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the "Quad", a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.

28 Oct 2011

Tenofovir gel confirmed to be effective against herpes in lab experiment, study shows

Data from lab experiments published online by the journal Cell Host and Microbes last week show that the gel form of the antiretroviral tenofovir, which is being investigated as an HIV prevention method, works to inhibit the reproduction of herpes virus in tonsil and cervical tissue, the New York Times reports.

24 Oct 2011

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA (darunavir) tablets to include 192-week data from the ARTEMIS study.

22 Oct 2011

HIV/AIDS clinic in Pakistan working to fight stigma, provide treatment

Inter Press Service reports on the Family Care Centre for people living with HIV/AIDS in Pakistan, which opened in Peshawar on September 1 "in the hope of breaking the stigma surrounding HIV/AIDS" in a region where myths surrounding the disease and its transmission are prevalent.

22 Oct 2011

E-voucher program providing food to malnourished Zimbabweans living with HIV, TB

An electronic voucher system, introduced by the World Food Programme (WFP) and implemented by the health ministry and non-governmental organizations, is helping Zimbabweans living with HIV/AIDS and tuberculosis (TB) and their families obtain food and fight malnutrition, PlusNews reports.

22 Oct 2011

Treating TB, HIV co-infections early, aggressively can save lives, multiple studies show

"Treating tuberculosis (TB) and HIV infections at the same time can be a challenge for patients and their doctors, but attacking both diseases early and aggressively isn't harmful and could save the lives of those who are sickest," according to a global study led by researchers from the University of California, San Francisco (UCSF) and published Wednesday in the New England Journal of Medicine (NEJM), the San Francisco Chronicle reports.

21 Oct 2011

Starting HIV therapy within two weeks of TB treatment increases survival by 33%

Timing is everything when treating patients with both HIV and tuberculosis. Starting HIV therapy in such patients within two weeks of TB treatment, rather than two months as is the current practice, increases survival by 33 percent, according to a large-scale clinical trial in Cambodia led by researchers at Children's Hospital Boston and the Immune Disease Institute.

20 Oct 2011

Study examines potential benefits of discordant couple HIV therapy

A new study published online in the journal AIDS uses mathematical models to predict the potential impact of treating discordant couples with antiretroviral therapy, according to a Columbia University Mailman School of Public Health press release.

20 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

Globe and Mail reports on death of Zambian HIV/AIDS advocate Winstone Zulu

Toronto's Globe and Mail reports on the death on Thursday of Winstone Zulu, an HIV/AIDS advocate from Zambia who lived with the virus for two decades. "His death has devastated the international community of AIDS activists," the newspaper writes.

18 Oct 2011

Health groups urge Secretary of U.S. Army to sustain funding for military HIV research program

"Speaking out against a potential $16 million cut in the Army's base research and development budget for HIV, leaders of the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) sent a letter Thursday to the Secretary of the U.S. Army, John McHugh, making the case for sustaining the U.S. Military HIV Research Program (MHRP)," according to the Center for Global Health Policy's "Science Speaks" blog.

15 Oct 2011

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck, known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.

14 Oct 2011